RXST insider transaction filings
RxSight, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-16. Screen RXST transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 10 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 4 legs across 4 filings by 4 insiders — 16,947 shares, $117,951 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 42.
- Largest priced transaction: sale of 7,765 shares @ $6.96 ($54,044) by Wilterding Mark, filed 2026-09-02.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Wilterding Mark — Chief Financial Officer | 2 | — | 1 leg · 7,765 sh · $54,044 | 4 |
| Kurtz Ronald M MD — Chief Medical Officer | 2 | — | 1 leg · 5,100 sh · $35,496 | 10 |
| Weinberg Eric — See remarks | 3 | — | 1 leg · 2,041 sh · $14,205 | 14 |
| Goldshleger Ilya — Chief Operating Officer | 2 | — | 1 leg · 2,041 sh · $14,205 | 12 |
| Mottiwala Aziz — President and CEO, Director | 1 | — | — | 2 |
Recent Form 4 filings — RxSight, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-16 | 4 | Weinberg Eric — See remarks | Option exercise (M): 35,168 @ $4.34 · Option exercise (M): 35,168 (derivative) @ $0 | EDGAR |
| 2026-09-09 | 4 | Weinberg Eric — See remarks | Disposition to issuer (D): 87,437 (derivative) · Disposition to issuer (D): 95,000 (derivative) · Disposition to issuer (D): 92,200 (derivative) · Disposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 125,000 (derivative) · Grant/award (A): 65,742 (derivative) · +4 more | EDGAR |
| 2026-09-09 | 4 | Wilterding Mark — Chief Financial Officer | Disposition to issuer (D): 258,770 (derivative) · Grant/award (A): 258,770 (derivative) | EDGAR |
| 2026-09-09 | 4 | Goldshleger Ilya — Chief Operating Officer | Disposition to issuer (D): 98,367 (derivative) · Disposition to issuer (D): 120,000 (derivative) · Disposition to issuer (D): 92,200 (derivative) · Disposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 125,000 (derivative) · Grant/award (A): 73,960 (derivative) · +4 more | EDGAR |
| 2026-09-09 | 4 | Kurtz Ronald M MD — Chief Medical Officer | Disposition to issuer (D): 338,819 (derivative) · Disposition to issuer (D): 200,000 (derivative) · Disposition to issuer (D): 149,000 (derivative) · Disposition to issuer (D): 215,000 (derivative) · Grant/award (A): 254,751 (derivative) · Grant/award (A): 173,913 (derivative) · +2 more | EDGAR |
| 2026-09-02 | 4 | Weinberg Eric — See remarks | Option exercise (M): 5,370 · Sale (S): 2,041 @ $6.96 · Option exercise (M): 5,370 (derivative) @ $0 | EDGAR |
| 2026-09-02 | 4 | Goldshleger Ilya — Chief Operating Officer | Option exercise (M): 5,370 · Sale (S): 2,041 @ $6.96 · Option exercise (M): 5,370 (derivative) @ $0 | EDGAR |
| 2026-09-02 | 4 | Wilterding Mark — Chief Financial Officer | Option exercise (M): 20,441 · Sale (S): 7,765 @ $6.96 · Option exercise (M): 20,441 (derivative) @ $0 | EDGAR |
| 2026-09-02 | 4 | Kurtz Ronald M MD — Chief Medical Officer | Option exercise (M): 13,425 · Sale (S): 5,100 @ $6.96 · Option exercise (M): 13,425 (derivative) @ $0 | EDGAR |
| 2026-07-24 | 4 | Mottiwala Aziz — President and CEO, Director | Grant/award (A): 2,312,138 (derivative) @ $0 · Grant/award (A): 571,286 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Warner Robert Keith — Director | Grant/award (A): 37,037 | EDGAR |
| 2026-06-18 | 4 | PALMISANO ROBERT J — Director | Grant/award (A): 37,037 | EDGAR |
| 2026-06-18 | 4 | Maniar Shweta — Director | Grant/award (A): 37,037 | EDGAR |
| 2026-06-18 | 4 | Fountain Tamara — Director | Grant/award (A): 37,037 | EDGAR |
| 2026-06-18 | 4 | LINK WILLIAM J PHD — Director | Grant/award (A): 37,037 | EDGAR |
| 2026-06-18 | 4 | Corley Jesse Anderson — Director | Grant/award (A): 37,037 | EDGAR |
| 2026-06-18 | 4 | COHEN RAYMOND W — Director | Grant/award (A): 30,864 | EDGAR |
| 2026-06-18 | 4 | Tammenoms Bakker Juliet — Director | Grant/award (A): 37,037 | EDGAR |
| 2026-06-18 | 4 | Andrews Julie — Director | Grant/award (A): 37,037 | EDGAR |
| 2026-04-20 | 4 | Goldshleger Ilya — Chief Operating Officer | Option exercise (M): 12,489 @ $4.13 · Option exercise (M): 12,489 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Wilterding Mark — Chief Financial Officer | Option exercise (M): 20,441 · Tax withholding (F): 8,068 @ $7.61 · Option exercise (M): 20,441 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Gaines Scott — Chief Customer Officer | Option exercise (M): 6,261 · Tax withholding (F): 2,580 @ $7.61 · Grant/award (A): 32,218 (derivative) @ $0 · Option exercise (M): 1,500 (derivative) @ $0 · Option exercise (M): 604 (derivative) @ $0 · Option exercise (M): 1,250 (derivative) @ $0 · +2 more | EDGAR |
| 2026-03-03 | 4 | Goldshleger Ilya — Chief Operating Officer | Grant/award (A): 32,218 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Weinberg Eric — See remarks | Grant/award (A): 32,218 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Kurtz Ronald M MD — President & CEO, Director | Grant/award (A): 80,545 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | Wilterding Mark — Chief Financial Officer | Grant/award (A): 258,770 (derivative) @ $0 · Grant/award (A): 163,528 (derivative) @ $0 | EDGAR |
| 2025-09-26 | 4 | Goldshleger Ilya — See remarks | Option exercise (M): 15,096 @ $4.34 · Option exercise (M): 8,349 @ $4.13 · Option exercise (M): 5,416 (derivative) @ $0 · Option exercise (M): 9,680 (derivative) @ $0 · Option exercise (M): 8,349 (derivative) @ $0 | EDGAR |
| 2025-08-04 | 4 | COHEN RAYMOND W — Director | Grant/award (A): 35,668 @ $0 | EDGAR |
| 2025-06-04 | 4 | LINK WILLIAM J PHD — Director | Grant/award (A): 10,752 | EDGAR |
| 2025-06-04 | 4 | Fountain Tamara — Director | Grant/award (A): 10,752 | EDGAR |
| 2025-06-04 | 4 | Warner Robert Keith — Director | Grant/award (A): 10,752 | EDGAR |
| 2025-06-04 | 4 | Maniar Shweta — Director | Grant/award (A): 10,752 | EDGAR |
| 2025-06-04 | 4 | PALMISANO ROBERT J — Director | Grant/award (A): 10,752 | EDGAR |
| 2025-06-04 | 4 | Andrews Julie — Director | Grant/award (A): 10,752 | EDGAR |
| 2025-06-04 | 4 | Tammenoms Bakker Juliet — Director | Grant/award (A): 10,752 | EDGAR |
| 2025-06-04 | 4 | Corley Jesse Anderson — Director | Grant/award (A): 10,752 | EDGAR |
| 2025-06-03 | 4 | Weinberg Eric — See remarks | Option exercise (M): 188,002 @ $3.93 · Option exercise (M): 188,002 (derivative) @ $0 | EDGAR |
| 2025-04-15 | 4 | Thunen Shelley B — See remarks | Option exercise (M): 7,792 @ $4.34 · Option exercise (M): 6,405 (derivative) @ $0 · Option exercise (M): 1,387 (derivative) @ $0 | EDGAR |
| 2025-03-13 | 4 | Fountain Tamara — Director | Sale (S): 7,000 @ $25.71 | EDGAR |
| 2025-02-27 | 4 | Weinberg Eric — See remarks | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | Goldshleger Ilya — See remarks | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | Thunen Shelley B — See remarks | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | Kurtz Ronald M MD — President & CEO, Director | Grant/award (A): 215,000 (derivative) @ $0 | EDGAR |
| 2025-01-27 | 4 | Maniar Shweta — Director | Sale (S): 3,519 @ $30.87 | EDGAR |
| 2025-01-17 | 4 | Corley Jesse Anderson — Director | Purchase (P): 1,443 @ $31.18 · Purchase (P): 1,767 @ $31.13 | EDGAR |
| 2024-12-03 | 4 | Goldshleger Ilya — See remarks | Option exercise (M): 3,105 @ $15.08 · Sale (S): 3,105 @ $46.08 · Option exercise (M): 3,105 (derivative) @ $0 | EDGAR |
| 2024-11-26 | 4 | Maniar Shweta — Director | Sale (S): 3,782 @ $45.88 | EDGAR |
| 2024-11-26 | 4 | Goldshleger Ilya — See remarks | Option exercise (M): 3,100 @ $15.08 · Sale (S): 3,100 @ $45 · Option exercise (M): 3,100 @ $15.08 · Sale (S): 3,100 @ $45.88 · Option exercise (M): 3,100 (derivative) @ $0 · Option exercise (M): 3,100 (derivative) @ $0 | EDGAR |
| 2024-11-18 | 4 | Goldshleger Ilya — See remarks | Option exercise (M): 4,875 @ $15.08 · Sale (S): 4,875 @ $46 · Option exercise (M): 3,100 @ $15.08 · Sale (S): 3,067 @ $45 · Sale (S): 33 @ $45.07 · Option exercise (M): 4,875 (derivative) @ $0 · +1 more | EDGAR |
| 2024-11-14 | 4 | Corley Jesse Anderson — Director | Purchase (P): 11,111 @ $45.37 · Purchase (P): 5,570 @ $45 · Purchase (P): 4,090 @ $44.98 · Purchase (P): 1,705 @ $44.50 | EDGAR |
Recent 8-K events — RxSight, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-15 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-16 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-19 | 8-K/A | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-02-25 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RXST returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →